CACNA2D2 and Parkinson disease: These include the calcium channel gene CACNA2D2, an established epileptic encephalopathy gene42 that is directly targeted by ten currently licensed drugs, including two ASMs (gabapentin and pregabalin) as well as the Parkinson’s disease drug safinamide and the nonsteroidal anti-inflammatory drug celecoxib.